Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coltuximab ravtansine
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Coltuximab ravtansine is an investigational antibody-drug conjugate composed of a chimeric monoclonal antibody targeting B-lymphocyte antigen CD19, a B-cell surface antigen, conjugated to the cytotoxic maytansinoid DM4 via a disulfide linker. The drug selectively binds to CD19 on B cells, leading to internalization and intracellular release of DM4, which inhibits tubulin polymerization and microtubule assembly. This mechanism disrupts cell division and induces apoptosis in malignant B cells. Coltuximab ravtansine was developed primarily for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and has also been investigated in precursor cell lymphoblastic leukemia/lymphoma. The drug was originally developed by ImmunoGen (now part of AbbVie), with clinical trials reaching phase II for DLBCL[1][2][3][4][5].
- Other names
- Maytansin-loaded anti-CD19 mAb
02
Targets
Beyond the preview
Go deeper on coltuximab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coltuximab ravtansine.